[Extracorporeal shockwave therapy in symptomatic heel spurs. An overview].
Extracorporeal shock wave application (ESWA) has been successfully used for years in routine clinical management of plantar fasciitis. So far no clinical trails have shown the efficiency in placebo-controlled protocols. This paper presents an overview of conservative and operative treatment modalities with respect to their efficacy. Results of a prospective randomized placebo-controlled double-blind multicenter trial to show efficiency and safety of ESWT are presented. In patients treated conservatively without success, a single shock wave application can improve the condition significantly compared with placebo treatment (p = 0.0149). The Roles and Maudsley score also showed a significant improvement between the groups, with 61.6% good or excellent results in the verum group and 39.7% in the placebo group (p = 0.0128). Therapy-related side effects (local swelling, petechia) are rare. The data presented in this study led to FDA approval in January 2002 of the shock wave device used.
Buch
M
M
Orthopädische Klinik, Kassel. M.Buch@okkassel.de
Knorr
U
U
Fleming
L
L
Theodore
G
G
Amendola
A
A
Bachmann
C
C
Zingas
C
C
Siebert
W E
WE
D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D036981:Fasciitis, Plantar / Q000628:therapy*; D005260:Female; D036982:Heel Spur / Q000628:therapy*; D006801:Humans; D008096:Lithotripsy; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D016896:Treatment Outcome